Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a significant growth in short interest in July. As of July 15th, there was short interest totaling 574,897 shares, a growth of 98.3% from the June 30th total of 289,957 shares. Based on an average trading volume of 30,260,865 shares, the short-interest ratio is presently 0.0 days. Approximately 16.9% of the shares of the stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision at the end of the most recent quarter. Institutional investors and hedge funds own 20.34% of the company’s stock.

Catheter Precision Price Performance

NYSEAMERICAN VTAK traded up $0.00 during trading hours on Wednesday, reaching $0.28. 1,236,975 shares of the stock traded hands, compared to its average volume of 4,397,643. The stock has a 50 day simple moving average of $0.83 and a two-hundred day simple moving average of $1.21. Catheter Precision has a 1 year low of $0.23 and a 1 year high of $4.31. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06. The company has a market cap of $1.02 million, a price-to-earnings ratio of -0.02 and a beta of -1.07.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings data on Monday, May 18th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. The firm had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.